PCR Perspectives
This major late-breaking trial from #EuroPCR 2026 highlights new insights from the CHAMPION AF study, one of the largest randomised trials comparing left atrial appendage closure (LAAC) with direct oral anticoagulants (DOACs) in patients with atrial fibrillation. In this interview, Philippe Garot and Jens Erik Nielsen-Kudsk discuss the pre-specified age subgroup analysis, showing consistent efficacy across younger and older populations, with significantly lower bleeding rates in the LAAC arm and very high procedural safety. They also explore how these findings could influence future patient selection and expand the role of LAAC in stroke prevention strategies for AF patients. ---------------------------------------- Hosted on Acast. See acast.com/privacy [https://acast.com/privacy] for more information.
53 episodios
Comentarios
0Sé la primera persona en comentar
¡Regístrate ahora y forma parte de la comunidad de PCR Perspectives!